Receptor targets
Retatrutide is characterized in the literature as a triple incretin receptor agonist — it engages three distinct class B G-protein-coupled receptors. The GIP and GLP-1 receptors are the two incretin receptors that mediate glucose-dependent insulin signaling, and the glucagon receptor adds a third axis to the molecule's pharmacology.
Combining agonism at all three receptors in one peptide is the defining feature that distinguishes retatrutide from earlier single- and dual-receptor incretin mimetics studied in the same field.
- GIP receptor (glucose-dependent insulinotropic polypeptide).
- GLP-1 receptor (glucagon-like peptide-1).
- Glucagon (GCG) receptor.
- Single molecule engineered for balanced tri-receptor agonism.
Mechanism of action
As a class B GPCR agonist, retatrutide binds the extracellular and transmembrane regions of each target receptor and drives Gs-coupled signaling, canonically raising intracellular cyclic AMP and downstream signaling in receptor-expressing cells. The GLP-1 and GIP arms represent the incretin axis studied for glucose-dependent insulin signaling, while the glucagon-receptor arm engages a distinct pathway associated in the research literature with hepatic and energy-metabolism signaling.
The scientific interest in a triagonist rests on the hypothesis that co-activating these complementary pathways in a single molecule produces a signaling profile different from activating any one or two of them alone. Study of this combined pharmacology in cellular and preclinical models is the subject of the peer-reviewed investigation into LY3437943.
Molecular design and half-life extension
Retatrutide is a synthetic peptide built on an incretin-analog backbone with engineered modifications that confer balanced potency across the three receptors and resistance to rapid enzymatic clearance. Like other long-acting incretin analogs, it incorporates a fatty-acid (lipidation) moiety that promotes reversible binding to serum albumin, a design strategy associated with an extended circulating half-life in the research literature.
These structural features — non-native residues and the acyl modification — are what allow a single synthetic molecule to act at three receptors while remaining stable enough for the pharmacology to be studied.
- Incretin-analog peptide backbone with non-native residues.
- Fatty-acid (lipidation) moiety for albumin binding and half-life extension.
- Engineered for balanced agonism across GIP, GLP-1, and glucagon receptors.
Dual vs triple: retatrutide vs tirzepatide
The clearest way to place retatrutide is against tirzepatide, the dual GIP/GLP-1 receptor agonist studied in the same research area. Tirzepatide activates two receptors — GIP and GLP-1 — whereas retatrutide adds a third target, the glucagon receptor, making it a triple agonist.
This added glucagon-receptor arm is the central pharmacological difference between the two molecules and the reason they are frequently compared in the literature. The comparison is developed in more detail in the dedicated comparison page.
- Tirzepatide: dual agonist — GIP + GLP-1 receptors.
- Retatrutide: triple agonist — GIP + GLP-1 + glucagon receptors.
- The glucagon-receptor arm is the defining additional target of retatrutide.
What the literature investigates
Peer-reviewed and preclinical research on LY3437943 examines its receptor binding and activation profile across the three targets, its pharmacokinetics, and its metabolic signaling effects in cellular and animal models. As a reference material, retatrutide is used to characterize triagonist pharmacology and as a comparator against dual and single agonists.
All such work is laboratory and preclinical in nature. Kairo Labs supplies retatrutide as a research reference compound for research use only; it is not for human or animal consumption, and nothing here describes any therapeutic use or dosing.
Verification and quality
Because retatrutide is a large, modified synthetic peptide, identity and purity confirmation matter. Each lot should carry a Certificate of Analysis reporting HPLC purity with the underlying chromatogram, mass-spectrometric identity comparing observed against theoretical mass, and net peptide content. Kairo Labs verifies to the lot, so every batch is tested and its data is retrievable.
See the COA guide for how to read those measurements, and the handling guides for reconstitution, storage, and stability of research peptides of this class.